Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GPC3 CART Cell
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Beijing 302 Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
Details : GPC3 CART Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 26, 2017
Lead Product(s) : GPC3 CART Cell
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Beijing 302 Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclophosphamide
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : RenJi Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)
Details : Cyclophosphamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lupus Erythematosus, Systemic.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 25, 2017
Lead Product(s) : Cyclophosphamide
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : RenJi Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAR-T Cell
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Shanghai Cancer Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CAR-T Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 08, 2016
Lead Product(s) : CAR-T Cell
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Shanghai Cancer Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TAI-GPC3-CAR-T
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
Details : TAI-GPC3-CAR-T is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 22, 2016
Lead Product(s) : TAI-GPC3-CAR-T
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
Details : Meso-Cart Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 11, 2016
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This drug candidate is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, B-Cell.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 03, 2016
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
